Pulmonary hypertension (PH) is a complex disease associated with a seven-fold increase in 1-year mortality compared to the general population [1]. Standardising the approach to diagnosis and clinical evaluation is a long-standing priority in PH, with progress across these objectives likely to underlie rising disease incidence and prevalence [2]. However, PH diagnosis remains delayed, and may take up to ~2 years in some patients, due to non-specific symptoms (often attributed to other diseases) and low index of clinical suspicion among non-specialists [2]. Advanced-stage disease is common at the time PH is finally recognised, hampering initiation of treatment earlier in the disease course, which, in turn, may be important for preventing disease progression [3].

肺动脉高压 (PH) 是一种复杂的疾病，与普通人群相比，一年死亡率增加七倍[1]。标准化诊断和临床评估方法是公共卫生领域的长期优先事项，这些目标的进展可能是疾病发病率和患病率上升的基础[2]。然而，由于非特异性症状（通常归因于其他疾病）和非专家的临床怀疑指数较低，PH 诊断仍然存在延迟，某些患者可能需要长达约 2 年的时间 [2]。当PH最终被识别时，晚期疾病很常见，这阻碍了在病程早期开始治疗，而这反过来可能对预防疾病进展很重要[3]。